glp-1 headaches Headache and receptor agonists: when medications are therapeutic and when they contribute to the symptom glp-1 headache Headaches are one

The future of oral tirzepatide The story of oral tirzepatide is not over

Acknowledgements This work was supported by the Burroughs Wellcome Fund (BWF) in Pathogenesis of Infectious Disease (PATH award to B.P.C., PATH award to S.H.), the National Institutes of Health (NIH) (R01AI173004 and R01AI179695 to B.P.C

Infertility and coeliac disease

This is significant when compared to a recent Blue Cross Blue Shield finding that over 30% of commercially insured adults prescribed GLP-1 treatment discontinue within the first four weeks, which may be because of discomfort with early side effects, the high cost of certain weight loss treatments, and limited access to care

10.1016/j.vph.2011.03.001 175 SharmaS.BhatiaV